Provided by Tiger Trade Technology Pte. Ltd.

Incyte

119.88
-1.4700-1.21%
Volume:430.91K
Turnover:51.77M
Market Cap:24.30B
PE:15.27
High:121.22
Open:121.05
Low:119.42
Close:121.35
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.02
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.83
PE(LYR):18.70

Loading ...

Incyte - Presents Phase 1/2 Data for Latarcibart Showing Substantial Bleed Reductions in Vwd Patients

THOMSON REUTERS
·
Jul 13

Incyte Says Phase 1/2 Data Show 81% Median Bleed-rate Cut with VWD Drug Latarcibart

Reuters
·
Jul 13

Incyte (INCY) Could Be 8% Overvalued After Its 22% Three Month Run

Simply Wall St.
·
Jul 13

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 11

Does Opzelura’s EU Setback and Index Exit Reframe the Bull Case For Incyte (INCY)?

Simply Wall St.
·
Jul 10

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 10

Press Release: Incyte to Report Second Quarter Financial Results

Dow Jones
·
Jul 08

Incyte Schedules Second-quarter Results Conference Call and Webcast

Reuters
·
Jul 08

Incyte is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 07

RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Adagene Posts Investor Presentation Highlighting Adg126 Masked Anti-ctla-4 Program in MSS Colorectal Cancer

Reuters
·
Jul 07

Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 07

Incyte Completes USD 1.25 Billion Acquisition of Vega Therapeutics

Reuters
·
Jul 06

Press Release: Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Its Hematology Portfolio

Dow Jones
·
Jul 06

Uk's MHRA Approves Retifanlimab for Treatment of Advanced Merkel Cell Skin Cancer

Reuters
·
Jul 06

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 03

US FDA Approves Orca Bio's Blood Cancer Therapy

Reuters
·
Jul 01

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 01

Incyte Price Target Maintained with a $140.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 29

Barclays Keeps Their Buy Rating on Incyte (INCY)

TIPRANKS
·
Jun 29